2. MAPK/ERK Pathway
  3. p38 MAPK JNK
  4. Hypaphorine

Hypaphorine is an indole alkaloid isolated from Caragana korshinskii. Hypaphorine has neurological and glucose-lowering effects. Hypaphorine prevents Lipopolysaccharides (LPS) (HY-D1056)-mediated acute lung injury (ALI) and proinflammatory response via inactivating the p38/JNK signaling pathway by upregulating DUSP1.

For research use only. We do not sell to patients.

Hypaphorine Chemical Structure

Hypaphorine Chemical Structure

CAS No. : 487-58-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in Water
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in Water In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Hypaphorine Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Hypaphorine

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK p38α p38β MAPK13 p38δ p38γ

View All JNK Isoform Specific Products:

View All Isoforms
JNK1 JNK2 JNK3 JNK

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Hypaphorine is an indole alkaloid isolated from Caragana korshinskii. Hypaphorine has neurological and glucose-lowering effects. Hypaphorine prevents Lipopolysaccharides (LPS) (HY-D1056)-mediated acute lung injury (ALI) and proinflammatory response via inactivating the p38/JNK signaling pathway by upregulating DUSP1[1][2][3][4].

In Vitro

Hypaphorine (6.25-100μM, 24 h) inhibits the Lipopolysaccharides (LPS) (HY-D1056)-mediated apoptosis of alveolar epithelial cells[2].
Hypaphorine (12.5-50 μM, 48 h) attenuates the expression of inflammatory factors (IL-1β, IL-6, TNF-α, and IL-18) and inactivates the p38/JNK signaling pathway through up-regulating DUSP1 in a dose-dependent manner[2].
Hypaphorine reverses inhibition of E. globulus seedling root growth induced by 3-Indoleacetic acid (indole-3-acetic acid) (HY-18569)[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Hypaphorine Related Antibodies

Apoptosis Analysis[2]

Cell Line: BEAS-2B lung epithelial cells
Concentration: 6.25, 12.5, 25, 50, 100 μM
Incubation Time: 24 h
Result: Cell viability was not changed when the dose was less than 50 μM, cell viability decreased significantly at 100 μM.
Cell viability was elevated dose-dependently (12.5, 25, 50 μM) in an ALI model.
The expression of pro-apoptotic proteins Bax and Caspase3 was dampened, while the anti-apoptotic protein Bcl2 was increased significantly in a dose-dependent manner.

RT-PCR[2]

Cell Line: BEAS-2B lung epithelial cells
Concentration: 12.5, 25, 50 μM
Incubation Time: 48 h
Result: Promoted the level of DUSP1 mRNA in dose-dependent manner.
DUSP1 was significantly upregulated after LPS treatment.

Western Blot Analysis[2]

Cell Line: BEAS-2B lung epithelial cells
Concentration: 12.5, 25, 50 μM
Incubation Time: 48 h
Result: Distinctly strengthened the DUSP1 expression and inactivated p38/JNK pathway.
Enhanced DUSP1 protein level and inactivated the p38/JNK signaling pathway after LPS treatment.
In Vivo

Hypaphorine (10 mg/kg; i.p.; 2 hours after the LPS injection) relieves LPS induced acute lung injury (ALI) in rats with anti-inflammatory effects[2].
Hypaphorine (50 mg/kg; i.p.; once) has antihyperglycemic activity[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male albino rats of Wistar/Sprague-Dawley strain (8-10 weeks, 160 g) made diabetic by intraperitoneal injection of Streptozotocin (HY-13753)[4]
Dosage: 50 mg/kg
Administration: Intraperitoneal injection (i.p.); once
Result: Showed significant anti-hyperglycemic activity (27.8% at 5 h and 20.4% at 24 h).
Animal Model: Male Sprague-Dawley rats (200-220 g) treated with LPS[2]
Dosage: 10 mg/kg
Administration: Intraperitoneal injection (i.p.); 2 hours after the LPS injection
Result: Alleviated the histological changes in lung tissues induced by LPS, including severe inflammatory cell infiltration, thickened alveolar walls, obvious diffuse edema, narrowed alveolar space, strengthened interstitial congestion, serious pathological damage and higher scores.
Reduced BALF cells and neutrophils increased by LPS.
Attenuated the wet/dry weight ratio, capillary permeability and d myeloperoxidase (MPO) activity facilitated by LPS.
Molecular Weight

246.31

Formula

C14H18N2O2
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC2=CC=CC=C12
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

H2O : 100 mg/mL (405.99 mM; Need ultrasonic)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.0599 mL 20.2996 mL 40.5992 mL
5 mM 0.8120 mL 4.0599 mL 8.1198 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (405.99 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 4.0599 mL 20.2996 mL 40.5992 mL 101.4981 mL
5 mM 0.8120 mL 4.0599 mL 8.1198 mL 20.2996 mL
10 mM 0.4060 mL 2.0300 mL 4.0599 mL 10.1498 mL
15 mM 0.2707 mL 1.3533 mL 2.7066 mL 6.7665 mL
20 mM 0.2030 mL 1.0150 mL 2.0300 mL 5.0749 mL
25 mM 0.1624 mL 0.8120 mL 1.6240 mL 4.0599 mL
30 mM 0.1353 mL 0.6767 mL 1.3533 mL 3.3833 mL
40 mM 0.1015 mL 0.5075 mL 1.0150 mL 2.5375 mL
50 mM 0.0812 mL 0.4060 mL 0.8120 mL 2.0300 mL
60 mM 0.0677 mL 0.3383 mL 0.6767 mL 1.6916 mL
80 mM 0.0507 mL 0.2537 mL 0.5075 mL 1.2687 mL
100 mM 0.0406 mL 0.2030 mL 0.4060 mL 1.0150 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Hypaphorine Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Hypaphorine487-58-1p38 MAPKJNKc-Jun N-terminal kinasePisolithustinctoriusneurologicalglucosep38/JNKacute lung injuryproinflammatoryInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Hypaphorine
Cat. No.:
HY-N2179
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (480 KB) Français - FR (480 KB) Deutsch - DE (480 KB) Norwegian - NO (480 KB) Español - ES (480 KB) Swedish - SV (480 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.